CD40 and focal segmental glomerulosclerosis: It has been proposed that anti-CD40 antibodies purified from the serum of patients with recurrent FSGS disrupt the podocyte structure by acting on F-actin filaments with the involvement of the suPAR–β3 integrin signaling pathway (78).